NMDA Receptor Channels: Labeling of MK-801 with Iodine-125 and Fluorine-18

D. M. WIELAND,* M. R. KILBOURN, D. J. YANG, E. LABORDE,
D. L. GILDERSLEEVE, M. E. VAN DORT, J-L. PIRAT,
B. J. CILIAX1 and A. B. YOUNG1

Division of Nuclear Medicine, Department of Internal Medicine and 1Department of Neurology,
University of Michigan Medical School, Ann Arbor, MI 48109, U.S.A.

(Received 19 April 1988)

Methods for labeling the glutamate channel blocking agent MK-801 with iodine-125 ($^{125}$I) and fluorine-18 ($^{18}$F) are described. Radioiodine was incorporated in the 1- or 3-positions of the aromatic ring of (+)MK-801 by solid-state halogen exchange techniques. Attachment of the [*$^{18}$F]fluoromethyl group to the bridgehead methyl position was achieved by reaction of [*$^{18}$F]fluoride with the triflamide alcohol 8 or the novel cyclic sulfamate 9 recently reported by Merck chemists. Radiochemical yields of (+)3-bromo-MK-801 were >72%, EOB; radiochemical purity >99%. In competitive binding studies using rat brain homogenates, (+)3-bromo-MK-801 showed greater affinity than (+)MK-801 for the glutamate-linked channel. The experimental log $P$ (2.1 ± 0.1) of MK-801 is optimal for transit of the blood–brain barrier. These preliminary findings support further testing of 3-[*$^{125}$I]iodo-MK-801 and (+)$^{18}$F-fluoromethyl-MK-801 as possible agents for in vivo mapping of the glutamate receptor complex.

Introduction

The amino acid glutamate is a major excitatory neurotransmitter in mammalian brain (Watkins and Evans, 1981). MK-801, a potent anticonvulsant and neuroprotective agent, has been shown to non-competitively bind to a subset of glutamate binding sites termed the N-methyl-d-aspartate (NMDA) receptor (Wong et al., 1986, 1988). Activation of the NMDA receptor opens a channel that permits $\text{Ca}^{2+}$ and other cations to pass into the neuron. It is to this channel, when in the open state, that MK-801 is thought to bind. The psychotropic drug phencyclidine (PCP) has also been shown to bind to this NMDA-operated open channel (Honey et al., 1985). However, MK-801 binds with greater affinity and specificity; it has a $K_D$ of 6.3 nM for the NMDA receptor channel and little affinity for the sigma opiate receptor (Wong et al., 1988).

The NMDA receptor complex may play a pivotal role in many brain diseases. Excessive stimulation of NMDA receptors has been implicated in neurodegenerative disorders such as Alzheimer's disease (Greenamyre et al., 1985; Deutsch and Morisha, 1988), psychotic processes (Olney, 1987), epilepsy (Meldrum, 1987) and ischemia-induced neuronal degeneration. Initial studies in animal models of both global and focal ischemia have shown that MK-801 protects against glutamate-induced neuronal damage when given before or shortly after the ischemic insult (Kemp et al., 1987).

The goal of this preliminary work was to explore strategies for synthesizing radiolabeled derivatives of MK-801 for in vivo mapping of the NMDA-linked cation channel. Both radioiodinated and $^{11}$C/$^{18}$F-tracers have been pursued in hopes of developing agents for evaluation by SPECT and PET, respectively. Synthetic routes to MK-801 and its analogs are described only in the patent literature; structure–activity relationship (SAR) studies have not been published. This report describes the synthesis of two isomeric $^{125}$I-labeled derivatives of (+)MK-801 and a [$^{18}$F]fluoromethyl derivative. Results of $K$ value determinations for these three derivatives suggest that two of the tracers merit in vivo evaluation as NMDA receptor channel markers.
Experimental

Materials and methods

(±)MK-801 [(±)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine] and its 13-hydroxy-
methyl derivative 1 were synthesized according to patent procedures (Anderson et al., 1983; Bender et al., 1984). The cyclic sulfamate 9 and its sulfonamide precursor 8 were obtained by a slight modification of the method of Lyle et al., 1987. Racemic 3-bromo-
MK-801 was a generous gift of Merck Sharp & Dohme Research Laboratories, West Point, Penn. Na[251] (no carrier added) and [3H]TCP were pur-
chased from Dupont/NEN.

Thin-layer chromatography (TLC) was performed on Whatman K6F silica gel glass-backed plates (250 μm). E. Merck neutral alumina plastic-backed plates (0.2 μm), or Whatman KC18F reverse phase glass-backed plates (200 μm). Sep-Paks™ were from Waters Associates. Flash chromatography was performed by the procedure of Still et al. (1978). High-pressure liquid chromatography (HPLC) was carried out on either a Waters system consisting of a Model 680 gradient controller, two Model 510 pumps, and Model U6K injector, or on a combined system composed of a Beckman Model 110B pump and a Rheodyne Model 7125 injection valve fitted with a 500 μL sample loop. Detection was performed with either a Kratos Model SF773 u.v./vis. detector at 230 nm or an ISCO Model UA-5 u.v. detector with a 280 nm filter, and a Beckman Model 170 or a Radio-
nematic Model DR/IC Flo-One radioisotope detector.

Melting points were determined on a Fisher-Johns melting point apparatus and are uncorrected. Radio-
TLC chromatograms were scanned on a Berthold Linear Analyzer LB 282. Infrared spectra were recorded on either a Perkin-Elmer 727B or a Nicolet 5X FT-i.r. spectrometer. 1H-NMR spectra were obtained on a Varian EM-360 (60 MHz), a Bruker AM-300 (300 MHz) or a Bruker WM-360 (360 MHz) instrument. 13C-NMR spectra were recorded on a Bruker WM 360 instrument at 90.5 MHz and are completely decoupled. Mass spectra were obtained on a Finnigan 4021 GCMS/DS (low resolution) or a VG70-250-S (high resolution) instrument. GC/MS analyses were done on a Hewlett-Packard 5890 gas chromatograph equipped with a mass selective de-
ector with a direct interface. Elemental analyses were performed by Spang Microanalytical Laboratories, Eagle Harbor, Mich.

In vitro binding assay

The affinity of the compounds for the NMDA-
linked receptor channel was determined using the procedure of Vignon et al., (1983, 1986) with modifi-
cations. Male Sprague–Dawley rats (250 g) were killed by decapitation. The cerebral cortices were dissected and homogenized for 15 s in 50 mL of Tris acetate buffer (50 mM, pH 7.2 at 4°C) using a Brinkmann tissue homogenizer. The crude mem-
brane receptor preparation was kept in an ice-cold bath until measurement of [3H]TCP binding. This measurement was performed by incubating 1 mL (triplicate aliquots) of the crude membrane sus-
pension (ca 45 mg of protein) with 20 μL of either a solution of the test compound in methanol or the buffer alone (total binding), and 1 mL of 6 nM [3H]TCP. Unlabeled TCP, 20 μL (20 μM final concentration) was used for determination of non-
specific binding.

The binding reaction was initiated by adding [3H]TCP to the membrane suspensions and allowing the tubes to stand at room temperature for 1 h. Incubation was terminated by rapid filtration through Whatman GF/B filters presoaked with 0.5% aqueous polyethylenimine. The filters were rapidly washed 3 times with 5 mL cold buffer and then suspended in 5 mL of Hydrofluor and allowed to stand at room temperature for 1.5 h before liquid scintillation counting. Protein concentrations were determined according to the method of Bradford (1976).

We previously reported saturation curves for [3H]TCP binding to rat brain homogenates (Albin et al., 1988). Scatchard analysis indicated a single class of binding sites with a mean Kd of 45 nM and a mean Bmax of 773 fmol/mg protein. In this study, the concentrations of unlabeled MK-801 derivatives displacing 50% of specific [3H]TCP binding (IC50) were determined. The binding affinity constants (Kd) were then calculated using the equation: Kd = IC50/(1 + [L]/Kd); the concentration of [3H]TCP ([L]) utilized in the inhibition studies was 6 nM.

Log P determination

The log P of MK-801 was determined according to the method of Frey et al. (1983), using unlabeled compound (free base) and octanol/phosphate buffered saline (PBS), pH 7.4. The amount of MK-
801 in the PBS phase was determined spectrophotomo-
etrically by extraction with ethyl ether, solvent removal, redissolving in absolute ethanol and comparison with a standard curve of free base MK-801 obtained in ethanol at 276.5 nm. Three determinations were made.

Preparation of (±)-1-indo-MK-801

To a solution of (±)MK-801 (315 mg, 1.40 mmol) in 85% H2SO4 (17 mL) were added silver sulfate (222 mg, 0.21 mmol) and iodine (181 mg, 0.71 mmol). The resulting mixture was stirred at room tem-
perature for 7 h. It was then cooled to 0°C and carefully neutralized with 10% NaOH. The neutral solution was extracted with CH2Cl2 (3 × 10 mL) and the combined extracts were dried over MgSO4 and concentrated in vacuo. GC/MS analysis of this crude material showed one major (tR = 9.59 min, ca 79% chemical yield) and two minor monooxidated products. Flash chromatography using hexane:ethyl acetate 1:1 provided a heart fraction (25 mg) of
the major isomer as a clear oil; $^1$H-NMR (CDCl$_3$): $\delta = 1.92$ (s, 3H, CH$_3$); 2.46–2.56 (m, 1H, NH); 2.59 (d, 1H, $J = 17.2$ Hz, $H_{1(a)}$); 3.23 (dd, 1H, $J = 17.2$, 5.7 Hz, $H_{1(b)}$); 4.73 (d, 1H, $J = 5.7$ Hz, $H_2$); 7.62 (dd, 1H, $J = 7.9$, 1.1 Hz, $H_3$); 6.82 (t, 1H, $J = 7.8$ Hz, $H_4$); 7.05–7.07 (m, $H_5$); 7.12 (td, 1H, $J = 7.3$, 1.5 Hz, $H_6$); 7.15 (td, 1H, $J = 7.3$, 1.6 Hz, $H_7$); 7.27–7.33 (m, 2H, $H_8$ and $H_9$); $^{13}$C-NMR (CDCl$_3$): $\delta = 20.08$ (CH$_3$); 41.67 (C$_1$); 58.63 (C$_2$); 64.19 (C$_3$); 103.83 (C$_4$); 118.64, 121.53, 126.95, 127.05, 127.57, 137.88, 135.21, 144.49, 146.60, 151.27; mass spectrum, $m/e$ 347 (M$^+$).

Treatment of this oil with HCl provided the corresponding hydrochloride salt: m.p. 205–207°C. Anal. Calc. for C$_{16}$H$_{16}$IN.HCl: C, 50.09; H, 3.94; N, 3.65. Found: C, 49.69; H, 3.69; N, 3.46.

**Synthesis of (+)-[125I]iodo-MK-801**

Radioiodide labeling was achieved by an ammonium sulfate catalysed solid-phase exchange technique described previously (Mangner et al., 1982; Otto et al., 1986). Exchanges were conducted in 3 mL septum sealed multi-dose vials with a disposable 10 cm$^3$ plastic syringe which served as the distillate condenser. Charcoal and aqueous sodium thiosulfate traps were connected in series with the condenser to trap any volatile radioiodine that was released during the heating process. In a typical procedure, a solution containing 6.3 mg of (NH$_4$)$_2$SO$_4$, 25 $\mu$g of (+)-3-bromo-MK-801, and 6.5 mCi of Na$^{125}$I in 300 $\mu$L of ethanol/water (1:1) was heated to dryness in an oil bath at 180°C. Air (10 mL) was slowly injected over a 1-min period, and the reaction mixture was maintained at 180–185°C for an additional 30 min. After cooling to room temperature, the reaction mixture was extracted with acetone (500 mL) and analyzed by radio-TLC (silica:Et$_2$O:CH$_2$CN:NH$_2$OH, 70:30:5; radiochemical yield 83%). Evaporation of the acetone left a residue which was extracted with CH$_2$Cl$_2$ (2 x 1.0 mL) and transferred to a silica Sep-Pak$^{\text{TM}}$. Elution with hexanes (10 mL) followed by EtOAc (5 mL) removed the less polar impurities. Further elution with CH$_3$CN (10 mL) afforded 1.67 mCi of (+)-[125I]iodo-MK-801 in >95% radiochemical purity as determined by radio-TLC. The radiochemical yield was 23%. HPLC was used for the preparative separation of (+)-3-[125I]iodo-MK-801 from the precursor (+)-3-bromo-MK-801. The separation was made on an Ultragel IP$^{\text{TM}}$ column with guard column [0.46 x (25 + 5) cm, 5-µm particle size, C-18; Phenomenex, Rancho Palos Verdes, Calif.]. With a mobile phase consisting of a mixture of 50 mM aqueous ammonium formate/CH$_3$CN (1:1) and a flow rate of 1.2 mL min$^{-1}$. Under these conditions, the retention times for 3-bromo-MK-801 and 3-[125I]iodo-MK-801 were 11.6 and 25.1 min, respectively. During elution of the radioactive peak, 1-min fractions were collected and the heart fractions were pooled.

The effective specific activity and radiochemical purity were assayed by radio-HPLC. The separation was made on an ultrasphere IP$^{\text{TM}}$ column with guard column [0.46 x (25 + 4.5) cm, 5-µm particle size, C-18; Beckman Instruments] with CH$_3$CN: 0.2 M ammonium formate (1:1) as eluant and a flow rate of 1.5 mL min$^{-1}$. For this system, the retention times of MK-801, 3-bromo-MK-801, and 3-[125I]iodo-MK-801 were 5.0, 8.8, and 10.9 min, respectively. To calculate the effective specific activity, the concentrations of both residual 3-bromo-MK-801 and 3-[125I]iodo-MK-801 were determined. The concentration of residual 3-bromo-MK-801 was determined by comparing the 3-bromo-MK-801 peak area with that of external standards, while that of 3-[125I]iodo-MK-801 was calculated by assaying the amount of 125I in an aliquot of the preparation in an autogamma counter (Model 1195; TM Analytic, Elk Grove Village, Ill.) and correcting for counting efficiency.

Prior to biological evaluation, the volume of the pooled heart fractions was reduced by evaporation under an argon stream at 40°C. The remaining aqueous layer was saturated with NaCl, and the radioligand was extracted into hexane. After evaporating the hexane under argon, the radioligand was formulated in ethyl alcohol/phosphate buffered saline, pH 6.5, (15:85).

**Preparation of tetrabutylammonium [18F]Fluoride**

[18F]Fluoride ion was produced by proton irradiation of [18O]water (86% isotopic enrichment,

**Calculation for C,,H,,IN.HCl: C, 50.09; H, 3.94; N, 3.65.**

**Chemical yield was 47%. The specific activity was observed up to 46 days after synthesis. Just prior to biological testing the solvent was evaporated and the compound was formulated in ethanol/5 mM sodium acetate buffer, pH 4.5.**

**Synthesis of (+)-[125I]iodo-MK-801**

In a typical procedure, a solution of (NH$_4$)$_2$SO$_4$ (5.0 mg in 15 $\mu$L of deionized H$_2$O), (+)-3-bromo-MK 801·HCl (100 $\mu$g in 100 $\mu$L of ethanol) and 7.27 mCi of Na$^{125}$I were combined and heated to dryness at 230°C in an oil bath. Air was then slowly passed through the reaction vial for 1 min. The dry mixture was maintained at 230°C for an additional 30 min, cooled to room temperature, dissolved in acetone (200 $\mu$L) and subjected to radio-TLC analysis (silica, CH$_3$CN:Et$_2$O:NH$_2$OH, 3:7:0.1). Following removal of the acetone by means of a gentle stream of argon, the dry reaction mixture was dissolved in CH$_2$Cl$_2$ (3 x 0.5 mL) and transferred to a silica Sep-Pak$^{\text{TM}}$. Elution with hexanes (10 mL) followed by EtOAc (5 mL) removed the less polar impurities. Further elution with CH$_3$CN (10 mL) afforded 1.67 mCi of (+)-[125I]iodo-MK-801 from the precursor (+)-3-bromo-MK-801. The separation was made on an Ultragel IP$^{\text{TM}}$ column with guard column [0.46 x (25 + 5) cm, 5-µm particle size, C-18; Phenomenex, Rancho Palos Verdes, Calif.]. With a mobile phase consisting of a mixture of 50 mM aqueous ammonium formate/CH$_3$CN (1:1) and a flow rate of 1.2 mL min$^{-1}$. Under these conditions, the retention times for 3-bromo-MK-801 and 3-[125I]iodo-MK-801 were 11.6 and 25.1 min, respectively. During elution of the radioactive peak, 1-min fractions were collected and the heart fractions were pooled.

The effective specific activity and radiochemical purity were assayed by radio-HPLC. The separation was made on an ultrasphere IP$^{\text{TM}}$ column with guard column [0.46 x (25 + 4.5) cm, 5-µm particle size, C-18; Beckman Instruments] with CH$_3$CN: 0.2 M ammonium formate (1:1) as eluant and a flow rate of 1.5 mL min$^{-1}$. For this system, the retention times of MK-801, 3-bromo-MK-801, and 3-[125I]iodo-MK-801 were 5.0, 8.8, and 10.9 min, respectively. To calculate the effective specific activity, the concentrations of both residual 3-bromo-MK-801 and 3-[125I]iodo-MK-801 were determined. The concentration of residual 3-bromo-MK-801 was determined by comparing the 3-bromo-MK-801 peak area with that of external standards, while that of 3-[125I]iodo-MK-801 was calculated by assaying the amount of 125I in an aliquot of the preparation in an autogamma counter (Model 1195; TM Analytic, Elk Grove Village, Ill.) and correcting for counting efficiency.

Prior to biological evaluation, the volume of the pooled heart fractions was reduced by evaporation under an argon stream at 40°C. The remaining aqueous layer was saturated with NaCl, and the radioligand was extracted into hexane. After evaporating the hexane under argon, the radioligand was formulated in ethyl alcohol/phosphate buffered saline, pH 6.5, (15:85).
Mound Laboratories) in an all-silver cyclotron target. Aliquots (1–200 mCi, 10–200 μL) were combined with 2 μmol of tetrabutylammonium hydroxide and evaporated in a Vacutainer™ essentially as per published methods (Brodack et al., 1986). The tetrabutylammonium [18F]fluoride was then resolubilized in 100–200 μL of dry acetonitrile and transferred to a suitable reaction vessel. Resolubilization efficiencies were 80–90%.

**Synthesis of (±)13-[18F]fluoromethyl MK 801**

To a solution of tetrabutylammonium [18F]fluoride in acetonitrile (100–200 μL) was added a solution of 1 mg of either triflamide alcohol 8 or cyclic sulfamate 9 in 50 μL acetonitrile, and the solution heated (100°C, closed vessel) for 5–15 min. The vessel was cooled slightly, then 200 μL of 6N HCl added and the aqueous mixture heated (100°C, closed vessel) for 5–15 min. The vessel was further washed with 5 mL of water. The product was crystallized to yield 2 pmol of tetrabutylammonium hydroxide and was then passed through a C-18 Sep-Pak, which was washed with 5 mL of CH3CN to give 27 mg (58%) of the azetidine 5 as a colorless oil.

**Synthesis of azetidine 5**

Trifluoromethane sulfonic anhydride (68 mg; 0.24 mmol) was added dropwise to a stirred solution of aminoalcohol 1 (50 mg; 0.20 mmol) in anhydrous CH3Cl3 at −78°C under dry nitrogen. The mixture was stirred at −78°C for an additional 45 min and then allowed to warm to room temperature over ca. 15 min. The reaction was quenched by addition of saturated aqueous NaHCO3 solution (1 mL); after stirring for 10 min, the aqueous layer was decanted and back-extracted with CH2Cl2 (3 × 3 mL). The combined organic layer and extracts were dried over MgSO4 and concentrated in vacuo. The crude product was purified by flash chromatography using hexane/ethyl acetate (2:1) and then 100% ethyl acetate to give 27 mg (58%) of the azetidine 5 as a colorless oil.

1H-NMR(CDC13): δ 2.42 (ddd, 1H, J = 9.6, 6.3, 1.5 Hz); 2.64 (dd, 1H, J = 16.6 Hz); 2.92 (ddt, 1H, J = 7.4(d), 9.4(t), 9.4(t) Hz); 3.12 (d, 1H, J = 9.2(d), 6.5(t), 6.5(t) Hz); 3.39 (d, 1H, J = 5.6 Hz); 3.40–3.44 (m, 1H); 4.42 (d, 1H, J = 5.1 Hz); 6.89–6.92 (m, 1H); 7.01–7.15 (m, 3H); 7.16–7.24 (m, 3H); 7.29–7.32 (m, 1H); MS (70 eV): m/e 233 (M+); HRMS: m/e calc. for C17H15N2: 233.2104; Found: 233.2108.

**Cyclic carbamate 6**

Di-t-butyl dicarbonate (92 mg; 0.42 mmol) in DMF (2 mL) was added to a stirred solution of amino alcohol 1 (100 μg; 0.40 mmol) in DMF (6 mL) under argon. The reaction mixture was stirred for 2 h at room temperature and then concentrated under vacuum. The residue was dissolved in CH2Cl2, washed rapidly with 5% HCl, and dried over anhydrous MgSO4. The solvent was removed under vacuum to give 90 mg (64%) of carbamate as a clear oil. Infrared (KBr): ν = 3440 (OH), 1680 (C=O) cm⁻¹; 1H-NMR (60 MHz, CDCl3): δ 1.35 (s, 9H, t-Bu); 2.48–2.70 (d, 1H, J = 17.6 Hz); 2.85–3.30 (m, 1H); 4.10–4.40 (m, 1H), 5.20–5.40 (d, 1H(H2)); 7.01–7.15 (m, 3H); 7.16–7.24 (m, 3H); 7.29–7.32 (m, 1H); MS (70 eV): m/e 277 (M+); HRMS: m/e calc. for C11H11NO: 277.1103. Anal. talc. for C11H11NO: C, 75.50; H, 5.63; N, 4.89. Found: C, 75.60; H, 5.67; N, 4.79.

**Results and Discussion**

**Chemistry**

The direct iodination of (±)MK-801 by the Derbyshire method (Derbyshire and Waters, 1950) provided an unexpectedly simple monoisotopated product pattern. It was anticipated that under conditions of stoichiometric excess of (±)MK-801 at least four compounds, the 2-, 3-, 7- and the 8-monoiodo
isomers might be formed. A major monoiodinated isomer was isolated from this reaction. The $^1$H and $^{13}$C NMR data, however, strongly support 1-iodo-MK-801 as the structure of this compound. The aromatic region of the $^1$H NMR spectrum clearly shows a coupling pattern suggesting substitution of one of the four protons ortho to the seven-membered ring (i.e. C$_7$H, C$_8$H, C$_9$H or C$_{10}$H). In addition, there is a small upfield shift in the signals of the two C$_7$-protons relative to parent MK-801, which can be attributed to a shielding effect by the iodine atom in the C$_7$ position. The last observation is reinforced by the significant downfield shift (ca 7.3 ppm), relative to MK-801, observed for C$_{11}$ in the $^{13}$C NMR spectrum of the iodo compound. This shift can be best attributed to the presence of the iodine atom in the adjacent C$_6$ position. Finally, direct comparison of the 'H and 13C NMR spectra of the monoiodo precursors from the desired radioactive product. This remarkable preference for electrophilic attack at the 1-position of MK-801 is unique to the Derbyshire reaction remains to be determined. The identity of the two minor monoiodinated products has not been pursued.

The radiosynthesis of (+)-[1-$^{125}$I]iodo-MK-801 was readily achieved by the solid-state radioiodide exchange method previously developed in this laboratory (Manger et al., 1983; Otto et al., 1986). Rapid passage of the reaction mixture through a silica Sep-Pak™ to eliminate unreacted radioiodide and other radioactive impurities was the only purification necessary. A radiochemical yield of 83% was obtained at a specific activity of 60 Ci/mmol; higher specific activities (>100 Ci/mmol) could be achieved but in lower yield.

The synthesis of (+)-3-[1-$^{125}$I]iodo-MK-801 was accomplished by interhalogen exchange with (±)-3-bromo-MK-801. Subsequent use of HPLC was needed to separate most of the (±)-3-bromo-MK-801 precursor from the desired radioactive product. This HPLC enrichment gave (±)-3-[1-$^{125}$I]iodo-MK-801 with an effective specific activity of >1350 Ci/mmol. The synthesis of unlabeled 3-iodo-MK-801 has not been reported and its synthesis is presently being pursued in our laboratory. Thus, the evidence for the identity of (±)-3-[1-$^{125}$I]iodo-MK-801 is indirect. The fact that only one radioactive organic product is formed and that its chromatographic behavior, both TLC and HPLC, is very similar to 3-bromo-MK-801, argues strongly for interhalogen exchange rather than proton-halogen exchange. Further support for interhalogen exchange rests on findings in our laboratory that ortho-chlorobenzylguanidine and PK-11195, an ortho-chlorophenyl derivative of isoquinoline, undergo exclusive interhalogen exchange with Na$_{125}$I under the solid-state conditions employed here for (±)-3-bromo-MK-801 (Gildersleeve et al., 1988).

The most obvious strategy for labeling MK-801 with a positron-emitting radioisotope is to synthesize N-[1-$^{11}$C]methyl-MK-801 with a 11C-labeled methylating agent (i.e. [11C]methyl iodide). This in fact has been done in our laboratory (Watkins G. L. and Jewett D. M., unpublished). However, as shown in Table 2, N-methyl-MK-801 has a 2-fold lower binding affinity than MK-801 in the $[^1]$HTCP assay. Thus, alternatives to labeling MK-801 with carbon-11 have been pursued, especially those employing $[^18]$F-fluoride ion because of its longer half-life, ease of large-batch synthesis, and high specific activity. Our attention focused on the bridgehead methyl group as a possible locus for incorporating $^{18}$F. This approach was attractive since the synthesis of the methylhydroxy derivative of MK-801, i.e. compound 1, has been described in the patent literature (Christy et al., 1979). It was predicted that the triflate of this alcohol, 2, could serve as a precursor to $^{18}$F-3, the 13-[18-F]fluoromethyl derivative of MK-801.

Alcohol 1 was synthesized in 7 steps from trans-10, 11-dibromodibenzoasuberenone. Reaction of 1 with 1.2 equivalents of triflic anhydride failed to give the desired triflate 2; instead the azetidine derivative 5 could be formed, seemingly through nitrogen attack on the triflate formed in situ. The azetidine was also observed in the reaction of 1 with DAST (Mislankar and Wieland, unpublished observation). Reaction of 1 with 2.5 equivalents of triflic anhydride gave the triflate sulfonamide 4. The imino group of 1 could be selectively functionalized as the t-BOC carbamate; however, subsequent attempts to form the triflate in the presence of organic bases resulted in intramolecular cyclization to the carbamate 6. Reaction of 1 with trityl chloride gave the O-alkylated product 7; reaction of 7 with triflic anhydride followed by an aqueous acid workup yielded the triflamide 8. At this stage in our synthetic work, Merck scientists reported...
a similar synthesis of triflamide 8 and detailed its anomalous reaction with Bu₄N⁺F⁻ to give 3 (Lyle et al., 1987). The Merck scientists have demonstrated that this unusual fluorination reaction proceeds through the in situ formation of the cyclic sulfamate 9 as shown in Fig. 1. Our results reported here, in which either the sulfonamide alcohol 8 or the cyclic sulfamate 9 give high and nearly identical radiochemical yields of ¹⁸F⁻ upon reaction with Bu₄N⁺F⁻/Bu₄N⁺OH⁻, supports this view. The identity of ¹⁸F⁻ was confirmed by TLC and HPLC comparison with authentic 3, synthesized by the Merck method. This anomalous radiochemical reaction is also remarkable in that it gives exceedingly high ¹⁸F incorporation and a product of high radiochemical purity (> 99%). Isolated yields are as high as 68% (93% corrected for decay); virtually the only other fluorine-18 species is unreacted [¹⁸F]fluoride ion which can be removed by a variety of methods, including liquid-liquid extraction or bonded-phase chromatography. Chemical impurities are few, but are apparently different depending on the choice of starting material. Trace chemical impurities such as 1 are removed from the final product by HPLC purification. With further optimization studies, it will likely be possible to eliminate the tracer chemical impurities by a simple Sep-Pak procedure. When aqueous HCl is used in the radiochemical workup of the [¹⁸F]fluoride reaction with the cyclic sulfamate 9, the chloromethyl analog 10 has been observed to form, seemingly through Cl⁻ attack on the cyclic sulfamate 9. Use of the hydroxytriflamide 8 gives no chloromethyl contaminant on aqueous HCl workup. Compound 10 was synthesized separately by reaction of 1 with thionyl chloride.

Fig. 1. Synthesis of (+)-13-[¹⁸F]fluoromethyl-MK-801.

**Table 2. MK-801 derivatives: binding affinities**

<table>
<thead>
<tr>
<th>Compound</th>
<th>Kᵢ ± SD (nM) *</th>
</tr>
</thead>
<tbody>
<tr>
<td>(+)MK-801</td>
<td>22 ± 2</td>
</tr>
<tr>
<td>(±)MK-801</td>
<td>79 ± 11</td>
</tr>
<tr>
<td>(±)N-Methyl-MK-801</td>
<td>158 ± 22</td>
</tr>
<tr>
<td>(±)l-Iodo-MK-801</td>
<td>790 ± 110</td>
</tr>
<tr>
<td>(±)l-Bromo-MK-801</td>
<td>0.8 ± 0.3</td>
</tr>
<tr>
<td>(±)l-Fluoromethyl-MK-801</td>
<td>79 ± 22</td>
</tr>
</tbody>
</table>

*N = 3.*

**Binding and log P studies**

Substitution of iodine in the 1-position decreases the binding affinity 10-fold (Table 2). Although unlabeled (+)-3-iodo-MK-801 was not available for competitive binding studies, it is noteworthy that (+)-3-bromo-MK-801, which is likely to mimic the 3-iodo isomer, has a 100-fold greater affinity than (+)MK-801 and a 1000-fold greater affinity than (±)-iodo-MK-801 for the TCP binding site. This high sensitivity to the halogen substitution pattern underscores the need to do further SAR studies.

Results of binding studies with (±)-N-methyl-MK-801 and (±)-13-fluoromethyl-MK-801, derivatives amenable to labeling with ¹³C and ¹⁸F, respectively, show that N-methylation slightly lowers binding affinity, whereas fluoromethylation of the bridgehead methyl group has no observable effect on binding. The radiotracers synthesized in this study are racemic ligands; however the (+) enantiomers are expected to show enhanced binding (See Table 2).

It has become clear in recent years that a "window" of lipophilicity exists for optimum passage of a drug or tracer through the blood-brain barrier (Hansch et al., 1987). This optimum log P is 2 ± 0.5. A log P value of 2.1 ± 0.1 was obtained for free base
MK-801. The addition of an iodine atom to MK-801 will likely raise the log $P$ to approximately 3; incorporation of the fluoromethyl group should have a lesser effect (Leo et al., 1971). In any case, CNS penetration should not be an obstacle for the tracer MK-801 derivatives synthesized in this study.

Conclusions

MK-801, a drug that binds with high affinity and selectivity to the glutamate-linked cation channel in mammalian brain, can be radiolabeled as a tracer for possible use in both SPECT and PET imaging techniques. This preliminary work lays the groundwork for a more detailed study of radiolabeled MK-801 derivatives as possible NMDA receptor-based imaging agents. It clearly demonstrates that foreign isotopes, both large ($^{125}$I) and small ($^{18}$F), can be incorporated into the MK-801 framework by conventional, high-yield methods without compromising the binding affinity. A number of reactions involving the MK-801 ring structure are unusual. One of these is the in situ formation of a cyclic sulfamate, provides an unexpectedly easy method for fluorine-18 labeling of MK-801. In vivo evaluation of $\left(\pm 1\right)^{\text{Iodo-MK-801}}$ and $\left(\pm 1\right)^{\text{Fluoromethyl-MK-801}}$ is in progress.

Acknowledgements—We gratefully acknowledge support of this research by the National Institute of Health (Grants NS25656 and NS15655). We thank Linder Markham for preparing the manuscript and Dr William Kerr for the use of the radiochemical laboratories at the Phoenix Memorial Laboratory, University of Michigan. We are also indebted to Dr Edward F. Domino for the use of his GC/MS unit.

References


